NephroDI Therapeutics, Inc.
NDI-5033, a small-molecule AMPK activator therapeutic for nephrogenic diabetes insipidus
- Sector
- Biotech
- Headquarters
- Philadelphia, PA
- Founded
- 2017
- Latest Form D
- $2M, Jun 2024
- Total capital
- $5M
- Federal grants
- $1.4M
- 2 awards · 2020–2025
- Rank in peer group#452 of 514
- Private capital raised
- $3.6M
- 2 Form D · last Jun 2024
- 28 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- first 2021
- Rank in peer group#109 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Novel AMPK activator for treatment of congenital X-linked nephrogenic diabetes insipidus in pediatric patients$1.1M
- Private capital raisedForm D · SEC · 2nd filing$2M
- Private capital raisedForm D · SEC · 1st filing$1.6M
- Federal grantHealth and Human S · Phase I · Novel AMPK Activators for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus$298K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
5months
from NephroDI Therapeutics, Inc.’s first federal award to its first private round.
- First federal award · Sep 2020
- Health and Human S · $298K
- First Form D · Feb 2021
- $1.6M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#109 · top 21%
- Linked publications#12 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Bibhash M. MukhopadhyayDirectorNamed in SEC Form D filings
- Chris M. GarabedianDirectorNamed in SEC Form D filings
- Donna M. SeeDirectorNamed in SEC Form D filings
- Fred M. CalloriDirectorNamed in SEC Form D filings
- Jeff M. Sands, M.D.Executive OfficerNamed in SEC Form D filings
- Michael GrissingerDirectorNamed in SEC Form D filings
Show all 7 people
- Rachael HaganExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 3- GrantedSubstituted Cycloalkanes For Managing Nephrogenic Diabetes InsipidusUSPTOUS 12,433,858
- GrantedSubstituted Cycloalkanes For Managing Nephrogenic Diabetes InsipidusUSPTOUS 11,844,770
- GrantedSubstituted Cycloalkanes For Managing Nephrogenic Diabetes InsipidusUSPTOUS 11,179,354
Recent research by its founders
- The urine-concentrating mechanism and urea transporters20260 cites
- Drinking Water NaCl Is Associated With Hypertension and Albuminuria: A Panel Study20255 cites
- Genes and Evolution of Urea Transporters20252 cites
Related companies, and why
- AvitideSimilar federal contract value in Biotech · null in contracts
- NEXGENIA, INC.Similar federal contract value in Biotech · null in contracts
- Terremoto BiosciencesSimilar federal contract value in Biotech · null in contracts
- Cerebral TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Lindy Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- NewcelX Ltd.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .